The global Insomnia Market size to exhibit a CAGR of 4.5% during the forecast period (2017-2023). Insomnia is a sleep disorder where the affected person finds it difficult to sleep. There are several causes that can trigger insomnia. In women, it can be a result of pregnancy, postpartum, and menopause. In general, it can be triggered by stress, anxiety, fatigue, and other psychological problems. At the same point of time, the rapid urbanization and industrialization in many urban areas can be considered for a work life imbalance owing to which cases of insomnia are increasing.
Factors that can trigger the insomnia market growth are advancement in technologies, new methods of therapies, and innovation in counselling. With the inclusion of digitalization, therapies are witnessing a drastic change in approach owing to which the insomnia market can undergo a paradigmatic shift. But the insomnia market can get hindered due to lack of awareness and healthcare structure.
Request Free Sample Report at: https://www.marketresearchfuture.com/sample_request/545
MRFR’s report on the insomnia market Top key Players includes
- Eisai, Co. (Japan)
- Sanofi (France)
- Merck & Co Inc (US)
- Pfizer, Inc. (US)
- Takeda Pharmaceutical Company (Japan)
- Flynn Pharma (UK)
- Meda Consumer Healthcare Inc (US)
- Pernix Therapeutics (US)
- Biocodex S A (France)
- Dainippon Sumitomo (Japan)
- Purdue Pharma L.P. (US)
- Consumer Healthcare Inc. (Canada)
- SkyePharma (UK)
- Johnson & Johnson (US)
- Astellas (UK)
- Neurim (Switzerland)
- ECR Pharmaceuticals (US)
- Vanda Pharmaceuticals Inc. (US).
These companies are instigating strategic developments in the global market owing to which the insomnia market can now envision prosperity in the coming years.
In 2019, researchers from the University of Virginia School of Medicine developed a new device called SHUTi to help people sleep better. The device is showing great clinical results as it is also reducing depression, anxiety, fatigue and other co-occurring conditions by a substantial margin, causes that triggers insomnia. The digital device uses cognitive behavioral therapy to treat insomnia in people.
MRFR, in their report on the global insomnia market, segmented it by types of therapy, drug formulation, and disease condition for a better look into the market prospect in the coming years.
On the basis of types of therapy, the insomnia market includes pharmacological therapy and non-pharmacological therapy. The pharmacological therapy segment includes non-benzodiazepines, benzodiazepines, melatonin receptor agonists, and others. The non-pharmacological segment comprises relaxation therapy, paradoxical intention, sleep hygiene education, cognitive behavioral therapy, stimulus control, and others. The pharmacological therapy segment is expected to showcase substantial growth as many of the drug’s bioavailability is fetching positive results. Meanwhile, cognitive behavioral therapy (CBT-1) can provide traction to the industry in the coming years.
Based on the drug formulation, the insomnia market includes capsules, tablets, and others. Impact of the development of the pharmaceutical sectors can trigger substantial rise for the market.
Based on the condition of the disease, the insomnia market includes poor quality of sleep, sleep maintenance and others.
Geographic analysis of the insomnia market conducted by MRFR includes North America, Europe, Asia Pacific (APAC) and the Middle East and Africa (MEA). The report intends to focus on a volume-wise and value-wise structure of the market to find out the demographic benefits that the insomnia market can offer.
Owing to increasing stress in the major cities across the region the insomnia market is finding it easy to grow in the market of North America. A report published by the Perelman School of Medicine at the University of Pennsylvania, 1 in 4 from the U.S. gets diagnosed with insomnia every year. The regional healthcare system eases the process of integrating advanced technologies and the latest treatments. However, favorable reimbursement policies can better the market prospect. Europe’s market relies mostly on the research and development of this sector. The regional market is riding on the thrust provided by R & D where the governments and private organizations are spending substantially to get better results.
Browse Full Research Report at: https://www.marketresearchfuture.com/reports/insomnia-market-545
The APAC and the MEA are not contributing much to the global rise of the market, and it can be put on lack of awareness. Healthcare structure in these regions are also a problem and can deter market growth. The work-life imbalance is quite high owing to which insomnia is on the rise. Japan is one such country that is getting affected by the disease most. Hence, the region can, in the coming years, register significant boost in the business.
Ask Report Details and Any Queries about Free Sample Report at: https://www.marketresearchfuture.com/enquiry/545
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028